{Reference Type}: Journal Article
{Title}: Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis.
{Author}: Menegaz de Almeida A;Leite M;Lopes LM;Gomes Lima P;Siegloch Barros ML;Rocha Pinheiro S;Andrade Í;Viana P;Morbach V;Marinheiro G;de Oliveira R;Pinheiro AC;
{Journal}: Expert Rev Neurother
{Volume}: 24
{Issue}: 9
{Year}: 2024 Sep 16
{Factor}: 4.287
{DOI}: 10.1080/14737175.2024.2367016
{Abstract}: <B>UNASSIGNED: </B>Gantenerumab is a monoclonal antibody targeting amyloid β protein (Aβ) in early Alzheimer's disease (AD). The authors sought to evaluate gantenerumab safety and efficacy in early AD patients.<BR><B>UNASSIGNED: </B>MEDLINE, Embase, and Cochrane databases were systematically searched until 2 December 2023. Data were examined using the Mantel-Haenszel method and 95% confidence intervals (CIs). Meta-regression analysis was conducted to evaluate a possible link between baseline Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) and amyloid-related imaging abnormalities (ARIA) at follow-up. R, version 4.2.3, was used for statistical analysis.<BR><B>UNASSIGNED: </B>A total of 4 RCTs and 2848 patients were included, of whom 1580 (55%) received subcutaneous gantenerumab. Concerning clinical scores, the placebo group achieved better rates of change in the Disease Assessment Scale (ADAS-Cog13) (SMD -0.11; 95% CI -0.19- -0.03; p = 0.008569; I2 = 0%). Gantenerumab was strongly associated with the occurrence of ARIA-E and ARIA-H: (19.67% vs. 2.31%; RR 9.46; 95% CI 5.55-16.11; p = <0.000001; I2 = 10%) and (21.95% vs. 12.38%; RR 1.79; 95% CI 1.50-2.13; p = <0.000001; I2 = 0%), respectively.<BR><B>UNASSIGNED: </B>In this meta-analysis, consistent results suggest that gantenerumab is not safe and efficient for early AD, showing no improvement in clinical scores for AD and being associated with the occurrence of ARIA-E and ARIA-H.